Drug Patents owned by Aurinia
1. List of Lupkynis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2023
(4 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(14 years from now) | |
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 2025-01-22
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
LUPKYNIS family patents
43
United States
22
Japan
10
Canada
9
European Union
7
China
7
Korea, Republic of
7
Australia
5
Israel
4
Spain
4
Austria
4
Denmark
4
Poland
4
Germany
4
Russia
4
Brazil
4
Norway
4
Croatia
4
Portugal
4
South Africa
3
Hong Kong
3
Yugoslavia
3
Morocco
3
New Zealand
3
Taiwan
3
Mexico
3
Ecuador
3
Colombia
3
Tunisia
2
Uruguay
2
Malaysia
2
Argentina
2
ME
2
Slovenia
1
IB
1
Singapore
1
Belgium
1
Chile
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic